Nurix Therapeutics Will Present Preclinical Data From NX-5948, Currently In Phase 1b For B-Cell Malignancies And In IND-Enabling Studies For Autoimmune Disease, And GS-6791/NX-0479 In Collaboration With Gilead Sciences And Also In IND-enabling...
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.